[1]张盼盼,薛 凌.PCSK9及Hcy水平对冠心病患者的临床意义[J].医学信息,2020,33(08):73-75.[doi:10.3969/j.issn.1006-1959.2020.08.024]
　ZHANG Pan-pan,XUE Ling.Clinical Significance of PCSK9 and Hcy Levels in Patients with Coronary Heart Disease[J].Medical Information,2020,33(08):73-75.[doi:10.3969/j.issn.1006-1959.2020.08.024]
点击复制

PCSK9及Hcy水平对冠心病患者的临床意义()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年08期
页码:
73-75
栏目:
论著
出版日期:
2020-04-15

文章信息/Info

Title:
Clinical Significance of PCSK9 and Hcy Levels in Patients with Coronary Heart Disease
文章编号:
1006-1959（2020）08-0073-03
作者:
张盼盼; 薛 凌
（锦州医科大学附属第三医院心内科，辽宁 锦州 121000）
Author(s):
ZHANG Pan-pan; XUE Ling
(Department of Cardiology,the Third Affiliated Hospital of Jinzhou Medical University,Jinzhou121000,Liaoning,China)
关键词:
冠心病; 前蛋白转化酶枯草溶菌素9; 同型半胱氨酸
Keywords:
Coronary heart disease; Proprotein convertase subtilisin 9; Homocysteine
分类号:
R541.4
DOI:
10.3969/j.issn.1006-1959.2020.08.024
文献标志码:
A
摘要:
目的 探讨前蛋白转化酶枯草溶菌素9（PCSK9）及同型半胱氨酸（Hcy）在冠心病患者中的变化及其临床意义。方法 选取2019年2月~9月我院收治的冠心病患者84例作为实验组，包括稳定性心绞痛（SAP）、不稳定性心绞痛（UAP）及急性心肌梗死（AMI）患者，另选取同期在我院体检的健康体检者43例作为对照组，比较两组甘油三酯（TG）、总胆固醇（TC）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）、载脂蛋白 A1（ApoA1）、载脂蛋白B（ApoB）、PCSK9及Hcy水平，比较SAP、UAP及AMI患者PCSK9水平。结果 实验组TC、LDL-C、Hcy及PCSK9水平均高于对照组，HDL-C低于对照组，差异均有统计学意义（P＜0.05）；两组TG、ApoA1、ApoB水平比较，差异无统计学意义（P＞0.05）；AMI患者血清PCSK9水平为（4.21±0.33）g/L，高于UAP患者的（3.58±0.35）g/L和SAP患者的（2.12±0.79）g/L，且UAP患者高于SAP患者，差异有统计学意义（P＜0.05）。结论 血浆Hcy、PCSK9水平上升可用于评估冠心病的严重程度，特别是PCSK9可辅助诊断急性冠脉综合征。
Abstract:
Objective To investigate the changes and clinical significance of proprotein convertase subtilisin 9 (PCSK9) and homocysteine (Hcy) in patients with coronary heart disease.Methods 84 patients with coronary heart disease admitted to our hospital from February to September 2019 were selected as the experimental group, including patients with stable angina pectoris (SAP), unstable angina pectoris (UAP) and acute myocardial infarction (AMI).43 healthy medical examinees in the hospital as a control group were compared triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), The levels of apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB),PCSK9 and Hcy levels were compared with those of SAP, UAP and AMI patients.Results The levels of TC, LDL-C, Hcy, and PCSK9 in the experimental group were higher than those in the control group, and HDL-C was lower than that in the control group,the differences were statistically significant (P<0.05);There was no significant difference in the levels of TG, ApoA1 and ApoB between the two groups (P>0.05); the serum PCSK9 level of AMI patients was (4.21±0.33) g/L, which was higher than that of UAP patients (3.58±0.35) g/L (2.12±0.79) g/L in SAP patients, and UAP patients were higher than SAP patients, the difference was statistically significant (P<0.05).Conclusion The increase of plasma Hcy and PCSK9 levels can be used to assess the severity of coronary heart disease, especially PCSK9 can help diagnose acute coronary syndrome.

参考文献/References:

[1]Niccoli G,Scalone G,Crea F.Acute myocardial infarction with no obstructive coronary atherosclerosis:mechanisms and management[J].European heart journal,2015,36(8):475-481.[2]Ference BA,Majeed F,Penumetcha R,et al.Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1,HMGCR,or both:a 2×2 factorial Mendelian randomization study[J].Journal of the American College of Cardiology,2015,65(15):1552-1561.[3]Filippatos TD,Kei A,Rizos CV,et al.Effects of PCSK9 inhibitors on other than low-density lipoprotein cholesterol lipid variables[J].Journal of Cardiovascular Pharmacology and Therapeutics,2018,23(1):3-12.[4]张秋焕,辛成德,钟白云.同型半胱氨酸和超敏C反应蛋白与冠状动脉粥样硬化性心脏病的相关性分析[J].中国现代医学杂志,2017,27(28):66-69.[5]林育辉,何晓青.游离脂肪酸、同型半胱氨酸和超敏C反应蛋白与冠状动脉病变的相关性[J].广东医学,2016,37(10):1516-1517.[6]李慧,王兴宁,赵冬.冠心病患者同型半胱氨酸、超敏C反应蛋白和心肌肌钙蛋白 T 检测的临床意义[J].国际检验医学杂志,2015,36(1):8-9.[7]Hopkins PN,Defesche J,Fouchier SW,et al.Characterization of autosomal dominant hypercholesterolemia caused by PCSK9 gain of function mutations and its specific treatment with alirocumab,a PCSK9 monoclonal antibody[J].Circulation:Cardiovascular Genetics,2015,8(6):823-831.[8]Jaworski K,Jankowski P,Kosior DA.PCSK9 inhibitors–from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade[J].Archives of Medical Science,2017,13(4):914-929.[9]Giunzioni I,Tavori H,Covarrubias R,et al.Local effects of human PCSK9 on the atherosclerotic lesion[J].The Journal of Pathology,2016,238(1):52-62.[10]Niccoli G,Scalone G,Crea F.Acute myocardial infarction with no obstructive coronary atherosclerosis:mechanisms and management[J].European Heart Journal,2015,36(8):475-481.[11]Han B,Eacho PI,Knierman MD,et al.Isolation and characterization of the circulating truncated form of PCSK9[J].Journal of Lipid Research,2014,55(7):1505-1514.[12]Leiter LA,Müller Wieland D,Baccara Dinet MT,et al.Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline:a pooled analysis of 10 phase Ⅲ ODYSSEY clinical trials[J].Diabetic Medicine,2018,35(1):121-130.[13]Stewart AFR,Dandona S,Chen L,et al.Kinesin family member 6 variant Trp719Arg does not associate with angiographically defined coronary artery disease in the Ottawa Heart Genomics Study[J].Journal of the American College of Cardiology,2009,53(16):1471-1472.[14]Chan K,Patel RS,Newcombe P,et al.Association between the chromosome 9p21 locus and angiographic coronary artery disease burden:a collaborative meta-analysis[J].Journal of the American College of Cardiology,2013,61(9):957-970.[15]张勇.探究同型半胱氨酸与血脂的相关性及 Hcy 在脑梗死中的诊断价值[J].当代医学,2019(9):55.[16]吕航吉,周广海,孙莎莎,等.高同型半胱氨酸血症诱导血管病变的机制及干预[J].泰山医学院学报,2017(1):112-116.[17]Shah H,Jan MU,Altaf A,et al.Correlation of hyper-homocysteinemia with coronary artery disease in absence of conventional risk factors among young adults[J].Journal of the Saudi Heart Association,2018,30(4):305-310.[18]Peng H,Man C,Xu J,et al.Elevated homocysteine levels and risk of cardiovascular and all-cause mortality:a meta-analysis of prospective studies[J].J Zhejiang Univ Sci B,2015,16(1):78-86.

相似文献/References:

[1]袁 帅,邢晓博,李 晓,等.MTHFR基因多态性与中年男性冠状动脉病变程度的相关研究[J].医学信息,2018,31(03):67.[doi:10.3969/j.issn.1006-1959.2018.03.021]
　YUAN Shuai,XING Xiao-bo,LI Xiao,et al.Association of MTHFR Gene Polymorphism with Coronary Artery Lesions in Middle-aged Men[J].Medical Information,2018,31(08):67.[doi:10.3969/j.issn.1006-1959.2018.03.021]
[2]张挺挺.经股和桡动脉介入治疗冠心病的临床疗效对比[J].医学信息,2018,31(03):114.[doi:10.3969/j.issn.1006-1959.2018.03.038]
　ZHANG Ting-ting.Comparison of Clinical Effects of Interventional Treatment of Coronary Heart Disease by Femoral and Radial Artery[J].Medical Information,2018,31(08):114.[doi:10.3969/j.issn.1006-1959.2018.03.038]
[3]迮艳华.稳心颗粒联合美托洛尔治疗冠心病心律失常的疗效分析[J].医学信息,2018,31(03):139.[doi:10.3969/j.issn.1006-1959.2018.03.049]
　ZE Yan-hua.Therapeutic Effect of Wenxin Granule Combined with Metoprolol on Arrhythmia of Coronary Heart Disease[J].Medical Information,2018,31(08):139.[doi:10.3969/j.issn.1006-1959.2018.03.049]
[4]张 旭.冠心病心绞痛患者进行护理干预的临床效果及 对护理质量影响研究[J].医学信息,2018,31(05):182.[doi:10.3969/j.issn.1006-1959.2018.05.068]
　ZHANG Xu.Clinical Effect of Nursing Intervention in Patients with Angina Pectoris of Coronary Heart Disease and its Influence on Nursing Quality[J].Medical Information,2018,31(08):182.[doi:10.3969/j.issn.1006-1959.2018.05.068]
[5]向明明,赵晓辉.黑龙江省东部地区汉族人群冠心病的危险因素研究[J].医学信息,2018,31(07):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
　XIANG Ming-ming,ZHAO Xiao-hui.Study on Risk Factors of Coronary Heart Disease in Han Nationality Population in Eastern Heilongjiang Province[J].Medical Information,2018,31(08):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
[6]王 坤,张永春.血清胆红素水平、单核细胞数、红细胞分布宽度与 冠状动脉病变程度的关系[J].医学信息,2018,31(08):53.[doi:10.3969/j.issn.1006-1959.2018.08.017]
　WANG Kun,ZHANG Yong-chun.Relationship between Serum Bilirubin Level,Monocyte Count,Red Blood Cell Distribution Width and Severity of Coronary Artery Disease[J].Medical Information,2018,31(08):53.[doi:10.3969/j.issn.1006-1959.2018.08.017]
[7]毛红岩.冠状动脉介入治疗冠心病的疗效及 对患者血清炎症因子的影响[J].医学信息,2018,31(10):77.[doi:10.3969/j.issn.1006-1959.2018.10.023]
　MAO Hong-yan.Effect of Coronary Intervention on Coronary Heart Disease and its Influence on Serum Inflammatory Factors[J].Medical Information,2018,31(08):77.[doi:10.3969/j.issn.1006-1959.2018.10.023]
[8]杨锦龙,刘 欢,吕秋菊,等.非糖尿病患者糖化血红蛋白和胰岛素抵抗与 冠状动脉病变程度的相关性研究[J].医学信息,2018,31(10):93.[doi:10.3969/j.issn.1006-1959.2018.10.028]
　YANG Jin-long,LIU Huan,LV Qiu-ju,et al.Correlation between Glycosylated Hemoglobin and Insulin Resistance and Severity of Coronary Artery Disease in Non-diabetic Patients[J].Medical Information,2018,31(08):93.[doi:10.3969/j.issn.1006-1959.2018.10.028]
[9]李 铎,王建华.盐酸曲美他嗪片辅助治疗对冠心病伴心力衰竭患者氧化应激、心肌功能的影响[J].医学信息,2018,31(10):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
　LI Duo,WANG Jian-hua.Effect of Trimetazidine Hydrochloride Tablets Adjuvant Therapy on Oxidative Stress and Myocardial Function in Patients with Coronary Heart Disease Complicated with Heart Failure[J].Medical Information,2018,31(08):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
[10]田跃雷.冠心病介入治疗后再狭窄的中西医防治[J].医学信息,2022,35(09):46.[doi:10.3969/j.issn.1006-1959.2022.09.011]
　TIAN Yue-lei.Prevention and Treatment of Restenosis After Percutaneous Coronary Intervention with Chinese and Western Medicine[J].Medical Information,2022,35(08):46.[doi:10.3969/j.issn.1006-1959.2022.09.011]

更新日期/Last Update: 2020-04-15